White Pine Capital LLC Purchases New Shares in NeoGenomics, Inc. $NEO

White Pine Capital LLC purchased a new position in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 147,720 shares of the medical research company’s stock, valued at approximately $2,712,000. White Pine Capital LLC owned 0.11% of NeoGenomics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Squarepoint Ops LLC grew its holdings in NeoGenomics by 118.3% during the 2nd quarter. Squarepoint Ops LLC now owns 222,036 shares of the medical research company’s stock worth $3,240,000 after acquiring an additional 120,342 shares during the period. WINTON GROUP Ltd bought a new position in shares of NeoGenomics during the 2nd quarter worth approximately $925,000. Bank of New York Mellon Corp acquired a new stake in shares of NeoGenomics during the 2nd quarter worth approximately $10,744,000. First Light Asset Management LLC increased its stake in shares of NeoGenomics by 26.2% in the 2nd quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock valued at $179,158,000 after acquiring an additional 2,549,545 shares in the last quarter. Finally, American Capital Management Inc. bought a new stake in shares of NeoGenomics in the 2nd quarter valued at $32,648,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. TD Cowen boosted their target price on shares of NeoGenomics from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. Craig Hallum restated a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a report on Wednesday, July 29th. Benchmark lifted their price target on shares of NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Piper Sandler reiterated an “overweight” rating on shares of NeoGenomics in a report on Wednesday, October 7th. Finally, Needham & Company LLC increased their price objective on shares of NeoGenomics from $19.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, October 6th. Eight research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, NeoGenomics has a consensus rating of “Moderate Buy” and a consensus price target of $20.88.

View Our Latest Report on NEO

NeoGenomics Stock Performance

NEO opened at $16.02 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 3.53 and a quick ratio of 3.31. NeoGenomics, Inc. has a fifty-two week low of $7.07 and a fifty-two week high of $20.15. The firm has a market capitalization of $2.07 billion, a PE ratio of -64.08 and a beta of 1.87. The company’s 50-day moving average is $17.55 and its 200 day moving average is $13.02.

NeoGenomics (NASDAQ:NEO – Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The medical research company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. The business had revenue of $209.25 million for the quarter, compared to analysts’ expectations of $206.70 million. NeoGenomics had a negative net margin of 4.10% and a negative return on equity of 0.99%. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.03 EPS. As a group, research analysts predict that NeoGenomics, Inc. will post -0.06 earnings per share for the current fiscal year.

NeoGenomics Company Profile

(Free Report)

NeoGenomics is a cancer-focused diagnostics company that provides laboratory testing and related services to physicians, hospitals, pharmaceutical companies and other healthcare organizations. Its clinical testing helps support the diagnosis and treatment of cancer. The company offers a range of oncology tests, including molecular, cytogenetic, pathology and flow cytometry services. Its capabilities also include next-generation sequencing and liquid biopsy testing, which can help clinicians assess tumor characteristics and inform treatment decisions.

See Also

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO – Free Report).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.